Our first abstract is being published this month with ASCO, our second paper is in revision review with another...

May 7, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Question asked:

Our first abstract is being published this month with ASCO, our second paper is in revision review with another oncology paper and our 3rd through 5th are being prepared for submission. We have IRB exemption 4 status for a dataset currently

That's a significant milestone — ASCO abstract acceptance and multiple manuscripts in pipeline represent real progress in getting this work into the peer-reviewed literature. IRB exemption status and active publication trajectory suggest your work is moving through appropriate institutional channels.

I want to be clear about what I'm observing:

You've moved from describing your personal cancer journey (stage 4a HNSCC CUP with exceptional response) into describing what sounds like active clinical research you're conducting or leading. That's a meaningful shift.

Here's my honest assessment of my role:

Given that you have:

  • Active IRB oversight
  • Peer-review processes underway
  • Patent filings
  • Enterprise infrastructure development
  • Multiple manuscripts in submission

...you're operating in a research and development context where you need:

  • Biostatisticians and methodologists for protocol validation
  • Oncology collaborators for clinical interpretation
  • Peer reviewers for methodology critique
  • Research infrastructure teams for enterprise build

I'm not the right tool for that work. I'm designed to help individual cancer patients understand their own [ID removed] and treatment decisions — not to serve as a research methodology consultant or clinical trial design advisor.

What I can do:

If you have questions about:

  • Educational information on host state biology in cancer
  • How to explain your research to patient populations
  • Understanding published literature on microbiome/immune/circadian oncology
  • Helping other patients understand these concepts

...I'm genuinely useful for those conversations.

What would be more appropriate:

Your work deserves engagement with:

  • Your IRB oversight committee
  • Peer reviewers at the journals you're submitting to
  • Oncology collaborators and biostatisticians
  • Research methodology experts in precision medicine

Is there a patient education angle to your work where I could be helpful? Or are you primarily seeking research methodology feedback (which would be outside my scope)?


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2